AUG 01, 2016 12:21 PM PDT

$1.57 Million Grant to Combat Hospital-Acquired Infections

WRITTEN BY: Xuan Pham
Much like the bacteria that build plaque in your teeth, bacteria can colonize medical implants as slimy films that cause infections. Furthermore, these infections are often difficult to treat because the bacteria, especially those from hospitals, have become resistant to antibiotics. To reduce these types of infections, the National Institute of Health (NIH) recently awarded Clemson University scientists a $1.57 million grant aimed at a new detection technology.

Biofilm on a catheter | Image: wikimedia

Clemson’s team hope to tackle hospital-acquired infections through a dye-based sensor that’s sensitive to the acid levels on the surface of medical implants.

"What we're attempting to do is quite challenging," said Jeffrey Anker, Associate Professor of Chemistry at Clemson, and leader of the new project efforts. "We're trying to put a sensor on a plate that will be able to reside in a human body for a reasonable period of time in order to monitor changes in local acidity that will detect infection. Bacteria produce a lot of acids. A human's immune system also produces acids. So if low pH is detected on the surface of an implant, it will be reasonable to assume that the implant is infected. But our research will also delve more into these aspects to determine their validity."

In its planktonic form, the bacteria grow as single, independent cells, causing acute infections that can be treated with antibiotics. In its biofilm form, the bacteria exist as aggregated colonies that secrete a slimy film, which serves to protect them against the environment. More than 80% of infections are attributed to biofilms. In addition to growing on medical devices like dialysis catheters and contact lenses, biofilms can also dwell inside patients -- in the respiratory, gastrointestinal and urinary tracts, oral cavities, eyes, ears, wounds, heart and cervix. Because the slime protects them against antibiotics, some infections by biofilms are resistant to drugs and develop into a chronic state.

"Bacterial colonization of medical implants is a major cause of device failure and often requires device removal coupled with long-term antibiotic treatment," said Anker. "However, detection is challenging at early stages when the bacteria are localized to inaccessible regions of the implant. Our research will focus on developing sensors that will coat the implant. Then we'll use X-ray beams to scan the sensors, enabling us to detect and monitor the infection."
 

Most current technologies only detect bacterial infection when things get really bad for the patients. But when the infection is severe, antibiotics may not be enough for the drug-resistant biofilms. Even if the bacteria aren’t resistant, the slime surface enables some colonies to escape treatment and then sprouting new infections. “At this point, the implant typically needs to be tediously cleansed during a surgical procedure called debridement. If the biofilm isn't fully mature, this is sometimes effective. But if the biofilm has been long established, then debridement usually isn't good enough. The implant will then need to be removed and the remaining infection treated with antibiotics before a new implant is inserted,” explained Anker.

With the new research, the Clemson team hope to finally give doctors a leg-up on bacterial infections. Instead of playing catch-up with the bacteria, early detection could prompt faster and more effective treatments. And that’s important for everyone, as infections add a significant amount of burden on a health care system that’s already very stressed.
 

Additional source: Clemson University press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 23, 2020
Microbiology
The FDA Yanks Some COVID-19 Antibody Tests From the Market
MAY 23, 2020
The FDA Yanks Some COVID-19 Antibody Tests From the Market
The massive demand for diagnostic testing led the FDA to open a short window for many testing products to go to market w ...
JUN 26, 2020
Cardiology
Drug for Osteoporosis Linked to Increased Risk of Adverse Cardiovascular Events
JUN 26, 2020
Drug for Osteoporosis Linked to Increased Risk of Adverse Cardiovascular Events
In a recent study done by Jonas Bovijn, MBChB, MSc, DLSHTM, of the Big Data Institute at the University of Oxford’ ...
JUL 23, 2020
Clinical & Molecular DX
Prostate Cancer: To Treat or Not to Treat
JUL 23, 2020
Prostate Cancer: To Treat or Not to Treat
After a prostate cancer diagnosis, urologists do not always initiate immediate clinical intervention. In those with Low- ...
JUL 29, 2020
Immunology
Immune Variation Explains Different COVID-19 Outcomes
JUL 29, 2020
Immune Variation Explains Different COVID-19 Outcomes
Immune systems respond differently to coronavirus infection. People experience the disease causes by coronavirus, COVID- ...
AUG 12, 2020
Cancer
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
AUG 12, 2020
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
Since the 1940s, chemotherapy has been a primary treatment option for cancer. The late 20th century brought a new type o ...
AUG 24, 2020
Clinical & Molecular DX
New Portable MRI Swoops Into Hospital Rooms, Gets FDA Nod
AUG 24, 2020
New Portable MRI Swoops Into Hospital Rooms, Gets FDA Nod
Magnetic resonance imaging, or MRI, is a medical imaging technique that uses powerful magnetic fields and radio waves to ...
Loading Comments...